The phase 3 SWOG S1216 trial has set a new benchmark for survival estimates for metastatic hormone-sensitive prostate cancer patients who have access to multiple approved subsequent life-prolonging therapies.
Findings from a new study show that pharmacologically inhibiting the H6PD protein can reverse drug resistance in human-derived preclinical models of enzalutamide-resistant prostate cancer.
Learn more about examples of groundbreaking research and new medical and surgical approaches that are leading the way in prostate cancer care.
An article published in the Cleveland Clinic Journal of Medicine outlines current guidelines in prostate cancer screening from the lens of a urologist practicing in the UK.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The decision to screen for prostate cancer is a complicated one. A Cleveland Clinic medical oncologist discusses overdiagnosis and recommends a new path forward.
When used with positron emission tomography, the agent rhPSMA-7.3 (18F) tags prostate-specific membrane antigen, a protein on the surface of the cancer cells, and identifies it on the scan.
Androgen-receptor (AR) antagonists can alter the metabolism of patients with prostate cancer, shows a recent study. And a transporter protein may become a new therapeutic target for kidney cancer.
Cleveland Clinic is now offering the IsoPSA™ test, a novel prostate-specific antigen assay, for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
A new test developed at Cleveland Clinic interrogates the HSD3B1 gene to determine if a prostate cancer patient has inherited the adrenal-permissive (1245C) or adrenal-restrictive (1245A) allele. The development of the test is an outgrowth of more than seven years of research at Cleveland Clinic.
Which research results from the American Society for Radiation Oncology’s 2019 annual meeting are the most interesting or clinically relevant? The staff of Cleveland Clinic Cancer Center’s Department of Radiation Oncology picks their Top 10.